Immunopathological Analysis in a French National Cohort of Membranous Nephropathy

Membranous Nephropathy Clinical Trial

— IHMN  

Official title:

Immunopathological Analysis in a French National Cohort of Membranous Nephropathy (IHMN)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04326218
• Other study ID #: 18-GIRCI-03
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 1, 2020
• Est. completion date: July 1, 2024

Study information

• Verified date: March 2020
• Source: Centre Hospitalier Universitaire de Nice
• Contact: Barbara SEITZ-POLSKI, MD
• Phone: +33 4 92 03 55 02
• Email: seitz-polski.b[@]chu-nice.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

National cohort of all cases of membranous nephropathy (MN) during a 1 year period in France, based on a pathological and/or serological diagnostic, collecting the data on:

• incidence of MN

• prevalence of anti-PLA2R1 and anti-THSD7A

• clinical outcome one year after diagnosis or after relapse (complete remission, partial remission or persistent nephrotic syndrome)

• environmental risk factors for the onset of MN

• HLA markers

• patient care status in France

Description:

Membranous nephropathy is a rare auto-immune disease, yet a major cause of nephrotic syndrome in adults. It is characterised by the deposition of antigen-antibody complexes on the glomerular basement membrane, leading to a decreased filtration rate and eventually kidney failure. About one third of cases have a favourable outcome without any treatment, another third requires a long term symptomatic treatment to manage their symptoms, and the last third of patients advances to end stage renal failure, requiring dialysis and kidney graft. MN can be associated with cancer, infections, other auto-immune diseases and with certain drugs (secondary MN), but most often it is idiopathic. In the latter form two antigens have been identified, PLA2R1 and THSD7A, with corresponding auto-antibodies in 70% and 2% of MN patients, respectively. GWAS studies identified several alleles associated with a higher risk of developing MN, however, since these are common variants they cannot explain the onset of MN in the vast majority of cases. Since MN is a rare disease, the number of new cases per each center is low, and nation-wide studies are needed to correctly evaluate its incidence and risk factors for the onset of MN, as well as validate previously published findings in monocentric studies on the prognostic value of PLA2R1 epitope spreading (immunisation against multiple domains of PLA2R1).

This study aims to establish a French national cohort of all cases of MN in a one year period in France. The inclusion will last one year with one additional year of follow-up, for a total of 2 years. In the first year, nephrologists of each associate centers in France will propose the study to each of their patients diagnosed with MN. In addition, clinical information will be collected, as well as a survey on patients' lifestyle habits. Serum samples will be sent for centralised analyses in Nice.

This study will help to clarify the results from single center studies, such as the prognostic value of epitope spreading. The information acquired on environmental risk factors will help us understand the pathophysiological mechanisms leading to the onset of MN et, by association, to other auto-immune diseases. With this knowledge, measures could be put in place to protect the population at risk.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 400
• Est. completion date: July 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 years or more

• Biopsy on a native kidney consistent with MN and/or positivity for serum anti-PLA2R1 and/or anti-THSD7A antibodies

• Signed informed consent

Exclusion Criteria:

• Diagnosis error based on the kidney biopsy staining or on serology analyses for the positivity for anti-PLA2R1 and/or anti-THSD7A

• Patients unable to give an informed consent

• Patients withdrawing an informed consent

Related Conditions & MeSH terms

• Glomerulonephritis, Membranous
• Kidney Diseases
• Membranous Nephropathy

Intervention

Other:
• Blood sample
Serum samples will be sent for centralised analyses in Nice. On these samples, different analysis will be performed : anti-PLA2R1 and anti-THSD7A antibodies anti-PLA2R1 and anti-THSD7A epitopes HLA typing

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the incidence of Membranous Nephropathy (MN) and its evolution	as either complete remission (UPCR < 0.3 g/g, serum albumin > 35 g/L, eGFR > 60 ml/min/1.73 m²) or partial remission (UPCR < 3.5 g/g and reduction of at least 50% from baseline, < 20% increase of serum creatinin from baseline) or persistent nephrotic syndrome (UPCR > 3.5 g/g, serum albumin < 30 g/L)	one year after inclusion
Secondary	Determination of incidence of primary and secondary forms of MN		24 months
Secondary	Identification of environmental factors associated with the onset of MN	Thanks to a specific questionnaire data on medical history, lifestyle, demography and profession will be collected; Medical history: prior diagnosis of any autoimmune disease, cancer, infection or other, infection in the month before the diagnosis of MN, thrombosis, drugs taken at the moment of diagnosis, allergies and type of symptomes; Emotional state: emotional state at diagnosis, stressful or destabilizing event in the year preceding diagnosis of MN	24 months
Secondary	Description of the standard of care for patients with MN in France	Treatment names and their duration (in weeks) will be collected	24 months
Secondary	the prognostic value of epitope spreading in patients with PLA2R1-associated MN	Epitope spreading status is determined by measuring the positivity to anti-CysR, anti-CTLD1 and CTLD7 antibodies in the serum, by the means of ELISA and expressed as RU/mL. The patients with antibodies targetting CysR only are considered as non-spreaders, while the patients additionnaly targetting either CTLD1 and/or CTLD7 are considered as spreaders. Epitope spreading status (non-spreader or spreader) will be correlated to clinical outcome (complete remission, partial remission or persistent nephrotic syndrome, as defined under primary outcome measures) one year after inclusion.	24 months
Secondary	Characterization of HLA typing of MN patients	Isolation of DNA and genotyping will be performed with the use of standard procedures of Next Generation Sequencing	12 months
Secondary	Prognostic value of tissue staining for glomerular deposit of PLA2R1, THSD7A, as welle as of different IgG subclasses	Positivity for PLA2R1, THSD7A and NELL-1 antigens will be determined using immunostaining with antibodies against PLA2R1, THSD7A and NELL-1, and Positivity for IgG1 IgG2, IgG3 and IgG4 subclasses will be determined using immunostaining with antibodies against IgG1 IgG2, IgG3 and IgG4, respectively, in glomeruli of kidney biopsy at inclusion. The positivity of tissue staining for PLA2R1, THSD7A and NELL-1or Ig subclasses will be correlated to the patient's clinical outcome one year after inclusion (complete remission, partial remission or persistent nephrotic syndrome, as defined under primary outcome measures).	12 months